Key clinical point: Addition of metformin to the neoadjuvant docetaxel, epirubicin, and cyclophosphamide (TEC) regimen did not improve disease outcomes in patients with breast cancer (BC) and metabolic abnormalities.
Major finding: The total pathological complete response was achieved by a similar proportion of patients receiving TEC vs TEC+metformin (12.5% vs 14.6%; P = .777). Neutrope nia and leucopenia, the most common grade ≥3 adverse events, were reported by 42.5% and 55.0% of patients in the TEC arm and 22.9% and 45.8% of patients in the TEC+metformin arm, respectively.
Study details: Findings are from the phase 2 NeoMET study including 92 patients with stage IIB/III BC and ≥1 metabolic syndrome component who were randomly assigned to receive six cycles of TEC or TEC+metformin.
Disclosures: This study was funded by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Huang J, Tong Y et al. Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: Results from the randomized phase II NeoMET trial. Breast Cancer Res Treat. 2022 (Dec 16). Doi: 10.1007/s10549-022-06821-y